Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778693) titled 'Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Shanghai Minwei Biotechnology Co., Ltd
Condition:
Overweight , Obesity
Intervention:
Drug: MWN109 1
Drug: MWN109 2
Drug: MWN109 3
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 1, 2026
Target Sample Size: 760
Countries of Recruitment:
China
To know more, visit https://clinicaltrials...